NASDAQ: ALZN
Linkedin Facebook-f Twitter Youtube Instagram
Alzamend Neuro, Inc.
  • About us
    • Corporate Overview
    • Management Team
    • Board of Directors
    • Board Committees
    • Board Diversity Matrix
    • Governance Documents
    • Scientific Advisory Board
  • Science
    • Product Pipeline
    • Publications
  • Investors
    • Overview
    • News & Events
    • Presentations
    • Company Info
    • Financial Results
    • Stock Data
    • SEC Filings
    • Governance
  • Contact
    • Contact Us
    • Careers
Menu
  • About us
    • Corporate Overview
    • Management Team
    • Board of Directors
    • Board Committees
    • Board Diversity Matrix
    • Governance Documents
    • Scientific Advisory Board
  • Science
    • Product Pipeline
    • Publications
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Presentations
    • Financial Results
    • Stock Data
    • SEC Filings
    • Governance
  • Contact
    • Contact Us
    • Careers

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Press Releases
    • In The News
    • IR Calendar
    • Email Alerts
  • Company Info
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Presentations
  • Financial Results
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Press Releases
  • In The News
  • IR Calendar
  • Email Alerts
Mar 22, 2023 8:00am EDT

Alzamend Neuro Announces Completion of Clinical Portion of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s

Mar 16, 2023 8:00am EDT

Alzamend Neuro Reports Third Fiscal Quarter Financial Results and Provides a Business Update

Jan 26, 2023 8:00am EST

Alzamend Neuro to Present at Sequire Biotechnology Conference

Jan 04, 2023 8:00am EST

Alzamend Neuro Partners With Biorasi to Conduct a First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase I/IIA Clinical Trial

Dec 28, 2022 8:00am EST

Alzamend Neuro Partners With the Miller School of Medicine, Interdisciplinary Stem Cell Institute at the University of Miami for ALZN002 Phase I/IIA Immunotherapy Vaccine Clinical Trial to Treat Mild to Moderate Dementia of the Alzheimer’s Type

Nov 15, 2022 8:00am EST

Alzamend Neuro CEO Stephan Jackman to Appear on Fox Business Network to Discuss Therapeutic Pipeline

Oct 31, 2022 8:00am EDT

Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type

Oct 05, 2022 8:00am EDT

Alzamend Neuro Announces Addition of Healthy Subjects to Ongoing Phase IIA Clinical Trial for AL001 in Alzheimer’s Subjects

Sep 29, 2022 8:00am EDT

Alzamend Neuro Submits IND Application for Phase I/IIA Trial for an Immunotherapy (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type

Sep 22, 2022 8:00am EDT

Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement

  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed

Making Alzheimer’s
Just a Memory™

About

  • Overview
  • Management
  • Board of Directors

Investor Relations

  • Overview
  • News & Events
  • Company Info
  • Presentations
  • Financial Results
  • Stock Data
  • SEC Filings
  • Governance

Other

  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Safe Harbor

© 2016-23 Alzamend Neuro, Inc. All rights reserved.

Linkedin Facebook-f Twitter Youtube Instagram
Skip to content